You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 4, 2024

Investigational Drug Information for ACT-541468


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug ACT-541468?

ACT-541468 is an investigational drug.

There have been 22 clinical trials for ACT-541468. The most recent clinical trial was a Phase 3 trial, which was initiated on June 4th 2018.

The most common disease conditions in clinical trials are Sleep Initiation and Maintenance Disorders, Disease, and Liver Diseases. The leading clinical trial sponsors are Idorsia Pharmaceuticals Ltd., Actelion, and University Hospital, Basel, Switzerland.

There are four US patents protecting this investigational drug and eighty-seven international patents.

Recent Clinical Trials for ACT-541468
TitleSponsorPhase
A Study to Investigate the Effects of Daridorexant on Nighttime Breathing in Patients With Shallow or Paused Breath During SleepIdorsia Pharmaceuticals Ltd.Phase 1
Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy SubjectsIdorsia Pharmaceuticals Ltd.Phase 1
A Clinical Study to Examine the Drug-drug Interactions Between ACT-541468 and Citalopram in Healthy Male and Female SubjectsIdorsia Pharmaceuticals Ltd.Phase 1

See all ACT-541468 clinical trials

Clinical Trial Summary for ACT-541468

Top disease conditions for ACT-541468
Top clinical trial sponsors for ACT-541468

See all ACT-541468 clinical trials

US Patents for ACT-541468

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ACT-541468 ⤷  Sign Up Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-meth- oxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist IDORSIA PHARMACEUTICALS LTD (Allschwil, CH) ⤷  Sign Up
ACT-541468 ⤷  Sign Up Benzimidazole-proline derivatives IDORSIA PHARMACEUTICALS LTD (Allschwil, CH) ⤷  Sign Up
ACT-541468 ⤷  Sign Up Benzimidazole-proline derivatives IDORSIA PHARMACEUTICALS LTD (Allschwil, CH) ⤷  Sign Up
ACT-541468 ⤷  Sign Up Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-- yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist IDORSIA PHARMACEUTICALS LTD (Allschwil, CH) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ACT-541468

Drugname Country Document Number Estimated Expiration Related US Patent
ACT-541468 Australia AU2014358743 2033-12-03 ⤷  Sign Up
ACT-541468 Brazil BR112016012625 2033-12-03 ⤷  Sign Up
ACT-541468 Canada CA2929720 2033-12-03 ⤷  Sign Up
ACT-541468 Chile CL2016001348 2033-12-03 ⤷  Sign Up
ACT-541468 China CN105793258 2033-12-03 ⤷  Sign Up
ACT-541468 Cyprus CY1119687 2033-12-03 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.